---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-039518"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2026-06-01T20:22:15+00:00"
generated_at: "2026-06-01T20:35:07.666843+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Esperion shareholders approve 7M-share increase to 2022 equity incentive plan

## Summary
- Stockholders approved Plan Amendment increasing 2022 Plan authorized shares by 7,000,000.
- J. Martin Carroll and Sheldon L. Koenig elected as Class I directors for terms ending 2029.
- Advisory vote on executive compensation approved with ~95.7M for, ~34.9M against.
- Ratification of Ernst & Young as auditor for FY2026 passed with ~167.1M for.
- All proposals passed at May 28, 2026 annual meeting.

## SEC filing metadata
- accession: 0001628280-26-039518
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2026-06-01T20:22:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/espr-20260528.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-039518
- JSON: https://secwatch.observer/filing/0001628280-26-039518.json
- Plain text: https://secwatch.observer/filing/0001628280-26-039518.txt

## Source-grounded claims
- claim_id: 0910c3811492c95f2d31303f1f3817387db9fd7a
  claim: Esperion Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-05-28 meeting.
  evidence_excerpt: The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm
- claim_id: 2536072c08ba76ad3f635334fd9ca34398baa79a
  claim: Esperion Therapeutics, Inc. shareholders approved Amendment to 2022 Equity Incentive Plan to increase shares by 7,000,000 at the 2026-05-28 meeting.
  evidence_excerpt: The Company’s stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 108,150,213 22,489,001 454,840 46,114,802
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm
- claim_id: 37f9ebbee0d9198d1ed11c68483cb682f191bd93
  claim: Esperion Therapeutics, Inc. shareholders approved Election of two Class I directors: J. Martin Carroll and Sheldon L. Koenig at the 2026-05-28 meeting.
  evidence_excerpt: The Company’s stockholders approved the Class I director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for Class I directors as follows: Class I Director Nominee For Withhold Broker Non-Votes J. Martin Carroll 105,082,565 26,011,489 46,114,802 Sheldon L. Koenig 109,672,941 21,421,113 46,114,802
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm
- claim_id: c699dd06e484bbd03024093ebf299b6d17c92d2f
  claim: Esperion Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-05-28 meeting.
  evidence_excerpt: The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 95,650,226 34,866,033 577,795 46,114,802
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.